FCMI
RGNX icon

Foresite Capital Management III’s Regenxbio RGNX Stock Holding History

Foresite Capital Management III’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100,000
Closed -$1.08M – 20
2016
Q1 		$1.08M Hold
100,000
– – 0.84% 19
2015
Q4 		$1.66M Buy
+100,000
New +$1.98M 1.47% 17

Other funds holding RGNX

BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Foresite Capital Management III's RGNX Position: Q2 2016 in Review

Foresite Capital Management III sold out of Regenxbio (RGNX) in Q2 2016, closing a stake of 100,000 shares — an estimated $1.08M sold.

Foresite Capital Management III first reported a position in RGNX in Q4 2015 and held it in 2 quarters. The position peaked at $1.66M in Q4 2015. 69 funds tracked by Wall St. Rank hold RGNX as of Q2 2016.

  • Foresite Capital Management III reported no remaining Regenxbio position as of Q2 2016 after selling out during the quarter.
  • Foresite Capital Management III sold 100,000 Regenxbio shares in Q2 2016, an estimated $1.08M.
  • Foresite Capital Management III first reported a position in Regenxbio in Q4 2015 and held it in 2 quarters.
  • Foresite Capital Management III's Regenxbio position peaked at $1.66M in Q4 2015.
  • 69 funds tracked by Wall St. Rank held Regenxbio as of Q2 2016.

Based on Foresite Capital Management III's 13F filing for Q2 2016, filed 12 Aug 2016.